Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare Rx Benefit Costs Will Exceed $400 Bil. – Rep. Waxman

Executive Summary

Medicare drug benefit legislation will ultimately cost well over the $400 bil. budget target, Rep. Henry Waxman (D-Calif.) predicted Oct. 29

You may also be interested in...



Medicare Rx “Benefits”: Drug Industry, PBMs Expected To Prosper

The possibility of a Medicare drug benefit leading to price controls is remote, Uwe Reinhardt, PhD, Princeton University, maintained during a Charles Schwab Capital Markets conference in Washington, D.C. Oct. 29

Canadian Rx Prices Are 14% Lower Than U.S., Merck-Funded Study Finds

The difference between U.S. and Canadian prescription drug prices is minimal when the relative cost of living is considered, a Health Affairs study says

Medicare Rx “Benefits”: Drug Industry, PBMs Expected To Prosper

The possibility of a Medicare drug benefit leading to price controls is remote, Uwe Reinhardt, PhD, Princeton University, maintained during a Charles Schwab Capital Markets conference in Washington, D.C. Oct. 29

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042749

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel